UB Paderborn / Katalog / Suche / in CDI

Abstract P4-07-09: Differential expression of microRNAs (miRNAs) in HER2 negative breast cancer (BC)

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P4-P4-07-09

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract P6-18-17: Ribociclib + letrozole in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (aBC) with no prior endocrine therapy (ET) for ABC: CompLEEment-1 trial, preliminary results from Spanish population

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P6-P6-18-17

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract P3-07-40: Pharmacogenetic study of exemestane and everolimus in metastatic breast cancer patients progressing on prior non-steroidal aromatase inhibitors

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P3-P3-07-40

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract GS4-02: Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor positive (HR+) early breast cancer (BC): Update of the combined TEXT and SOFT trials

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.GS4-02-GS4-02

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract GS4-03: Randomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (OFS) versus tamoxifen in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Update of the SOFT trial

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.GS4-03-GS4-03

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract P4-13-10: Stomatitis following everolimus (EVE) plus exemestane (EXE) in patients with hormone receptor-positive (HR+), HER2– advanced breast cancer (ABC) in the BALLET trial (CRAD001YIC04)

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P4-P4-13-10

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract P4-21-16: Phase III trial to evaluate patient´s preference for subcutaneous versus intravenous trastuzumab administration in patients with HER2 positive advanced breast cancer (ABC) under IV trastuzumab (IV-t) treatment for at least 4 months. ChangHER-SC study (GEICAM/2012-07)

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P4-P4-21-16

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract OT2-01-04: SOLAR-1: A phase III study of alpelisib and fulvestrant in men and postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (BC) progressing on or after aromatase inhibitor (AI) therapy

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.OT2-01-04-OT2-01-04

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract OT2-01-06: Phase III study of p albociclib (PD-0332991) in combination with e ndocrine therapy (exemestane or fulvestrant) versus chemotherapy (capecitabine) in hormonal receptor (HR) positive/HER2 negative metastatic breast cancer (MBC) patients with r esistance to a romatase inhibitors. “The PEARL study” (GEICAM/2013-02)

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.OT2-01-06-OT2-01-06

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract P4-07-07: Analysis of miRNAs and proteins relations in breast cancer

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.P4-P4-07-07

2013

Link zum Volltext

Verfügbarkeit prüfen

P2-14-09: Comparison between Spanish and Peruvian Patients with Early Breast Cancer

Cancer research (Chicago, Ill.), 2011-12, Vol.71 (24_Supplement), p.P2-P2-14-09

2011

Link zum Volltext

Verfügbarkeit prüfen

P3-05-06: Progression of Breast Cancer Molecular Subtypes through Different Clinical Stages

Cancer research (Chicago, Ill.), 2011-12, Vol.71 (24_Supplement), p.P3-P3-05-06

2011

Link zum Volltext

Verfügbarkeit prüfen

Abstract P5-10-11: Clinical significance of microRNA expression as a prognostic factor in early N+ breast cancer (BC)

Cancer research (Chicago, Ill.), 2012-12, Vol.72 (24_Supplement), p.P5-P5-10-11

2012

Link zum Volltext

Verfügbarkeit prüfen

Abstract P2-16-04: A phase 2 study of ridaforolimus (RIDA) and dalotuzumab (DALO) in estrogen receptor positive (ER+) breast cancer

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.P2-P2-16-04

2013

Link zum Volltext

Verfügbarkeit prüfen

P4-09-34: Luminal Infiltrating Lobular Carcinoma of the Breast: Clinical and Prognostic Features

Cancer research (Chicago, Ill.), 2011-12, Vol.71 (24_Supplement), p.P4-P4-09-34

2011

Link zum Volltext

Verfügbarkeit prüfen

Abstract P2-16-01: Overall Survival Data from SOLTI-0701: A Multinational, Double-Blind, Placebo-Controlled, Randomized Phase 2b Study Evaluating the Oral Combination of Sorafenib and Capecitabine in Patients with Locally Advanced or Metastatic HER2-Negative Breast Cancer

Cancer research (Chicago, Ill.), 2010-12, Vol.70 (24_Supplement), p.P2-P2-16-01

2010

Link zum Volltext

Verfügbarkeit prüfen

P5-14-22: Prospective Observational Study To Describe the Clinicopathological and Biological Characteristics and the Management of Metastatic Breast Cancer Patients Who Experienced Complete or Partial Remission or Disease Stabilization during at Least 3 Years

Cancer research (Chicago, Ill.), 2011-12, Vol.71 (24_Supplement), p.P5-P5-14-22

2011

Link zum Volltext

Verfügbarkeit prüfen

Abstract P6-07-21: High reduction of circulating tumour cells in HER2-negative locally advanced or metastatic breast cancer (LAMBC) patients treated with eribulin as third line chemotherapy (ONSITE study)

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P6-P6-07-21

2017

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of the administration of bevacizumab in combination with first-line chemotherapy for the treatment of advanced breast carcinoma: ATHENA MO19391 study results in Spanish patients

Breast cancer research : BCR, 2009-01, Vol.11 (S1), p.P24-P24, Article P24

2009

Link zum Volltext

Verfügbarkeit prüfen

Radiation recall dermatitis induced by pegylated liposomal doxorubicin

Anti-cancer drugs, 2003-08, Vol.14 (7), p.575-576

2003

Link zum Volltext

Verfügbarkeit prüfen

Abstract PD01-01: Cetuximab + Cisplatin in Estrogen Receptor-Negative, Progesterone Receptor-Negative, HER2-Negative (Triple-Negative) Metastatic Breast Cancer: Results of the Randomized Phase II BALI-1 Trial

Cancer research (Chicago, Ill.), 2010-12, Vol.70 (24_Supplement), p.PD01-01-PD01-01

2010

Link zum Volltext

Verfügbarkeit prüfen

Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

The New England journal of medicine, 2015-02, Vol.372 (8), p.724-734

2015

Link zum Volltext

Verfügbarkeit prüfen

Una nueva especie de Aphis Linnaeus, 1758 (Hemiptera, Aphididae) recogida sobre Gymnophyton Clos (Apiaceae) en Argentina

Graellsia, 2017-06, Vol.73 (1), p.e055-e055

2017

Link zum Volltext

Verfügbarkeit prüfen

Discapacidad y capacidad laboral

Medicina y Seguridad del Trabajo, 2014, Vol.60 (suppl 1), p.189-195

Redondo Ciruelos, Victoriano

2014

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Abstract P4-07-09: Differential expression of microRNAs (miRNAs) in HER2 negative breast cancer (BC)

Abstract P6-18-17: Ribociclib + letrozole in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (aBC) with no prior endocrine therapy (ET) for ABC: CompLEEment-1 trial, preliminary results from Spanish population

Abstract P3-07-40: Pharmacogenetic study of exemestane and everolimus in metastatic breast cancer patients progressing on prior non-steroidal aromatase inhibitors

Abstract GS4-02: Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor positive (HR+) early breast cancer (BC): Update of the combined TEXT and SOFT trials

Abstract GS4-03: Randomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (OFS) versus tamoxifen in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Update of the SOFT trial

Abstract P4-13-10: Stomatitis following everolimus (EVE) plus exemestane (EXE) in patients with hormone receptor-positive (HR+), HER2– advanced breast cancer (ABC) in the BALLET trial (CRAD001YIC04)

Abstract P4-21-16: Phase III trial to evaluate patient´s preference for subcutaneous versus intravenous trastuzumab administration in patients with HER2 positive advanced breast cancer (ABC) under IV trastuzumab (IV-t) treatment for at least 4 months. ChangHER-SC study (GEICAM/2012-07)

Abstract OT2-01-04: SOLAR-1: A phase III study of alpelisib and fulvestrant in men and postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (BC) progressing on or after aromatase inhibitor (AI) therapy

Abstract P4-07-07: Analysis of miRNAs and proteins relations in breast cancer

P2-14-09: Comparison between Spanish and Peruvian Patients with Early Breast Cancer

P3-05-06: Progression of Breast Cancer Molecular Subtypes through Different Clinical Stages

Abstract P5-10-11: Clinical significance of microRNA expression as a prognostic factor in early N+ breast cancer (BC)

Abstract P2-16-04: A phase 2 study of ridaforolimus (RIDA) and dalotuzumab (DALO) in estrogen receptor positive (ER+) breast cancer

P4-09-34: Luminal Infiltrating Lobular Carcinoma of the Breast: Clinical and Prognostic Features

Abstract P2-16-01: Overall Survival Data from SOLTI-0701: A Multinational, Double-Blind, Placebo-Controlled, Randomized Phase 2b Study Evaluating the Oral Combination of Sorafenib and Capecitabine in Patients with Locally Advanced or Metastatic HER2-Negative Breast Cancer

P5-14-22: Prospective Observational Study To Describe the Clinicopathological and Biological Characteristics and the Management of Metastatic Breast Cancer Patients Who Experienced Complete or Partial Remission or Disease Stabilization during at Least 3 Years

Abstract P6-07-21: High reduction of circulating tumour cells in HER2-negative locally advanced or metastatic breast cancer (LAMBC) patients treated with eribulin as third line chemotherapy (ONSITE study)

Efficacy and safety of the administration of bevacizumab in combination with first-line chemotherapy for the treatment of advanced breast carcinoma: ATHENA MO19391 study results in Spanish patients

Radiation recall dermatitis induced by pegylated liposomal doxorubicin

Abstract PD01-01: Cetuximab + Cisplatin in Estrogen Receptor-Negative, Progesterone Receptor-Negative, HER2-Negative (Triple-Negative) Metastatic Breast Cancer: Results of the Randomized Phase II BALI-1 Trial

Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

Una nueva especie de Aphis Linnaeus, 1758 (Hemiptera, Aphididae) recogida sobre Gymnophyton Clos (Apiaceae) en Argentina

Discapacidad y capacidad laboral

Suchergebnisse filtern